Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay-Reference-Cited by-同舟云学术

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

Published:2019-01-30 Issue:477 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Berkhout Lea C.¹^ORCID,l’Ami Merel J.²^ORCID,Ruwaard Jill²,Hart Margreet H.¹,Heer Pleuni Ooijevaar-de¹,Bloem Karien¹,Nurmohamed Michael T.²³^ORCID,van Vollenhoven Ronald F.²³⁴,Boers Maarten³⁵^ORCID,Alvarez Daniel F.⁶,Smith Catherine H.⁷^ORCID,Wolbink Gerrit J.¹²^ORCID,Rispens Theo¹^ORCID

Affiliation:

1. Department of Immunopathology, Sanquin Research, 1066 CX Amsterdam, Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.

2. Amsterdam Rheumatology and immunology Center, Reade, 1056 AB Amsterdam, Netherlands.

3. Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, VU University Medical Center, 1081 HV Amsterdam, Netherlands.

4. Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Academic Medical Center, 1105 AZ Amsterdam, Netherlands.

5. Department of Epidemiology and Biostatistics, VU University Medical Center, 1081 HV Amsterdam, Netherlands.

6. Pfizer Inc., Collegeville, PA 19426, USA.

7. St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, Kings College London, SE1 9RT London, UK.

Abstract

TNF concentrations stabilize in patients with rheumatoid arthritis during long-term adalimumab therapy and are associated with antidrug antibodies.

Funder

ZonMW

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference37 articles.

1. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis;Charles P.;J. Immunol.,1999

2. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

3. Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-αand Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

4. Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis

5. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25

2. Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment;mAbs;2024-07-02

3. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs;Clinical Rheumatology;2024-05-22

4. Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data;Pediatric Drugs;2024-04-17

5. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy;Frontiers in Immunology;2024-02-29